A non-consensus investment begins with a disagreement. It becomes an investment strategy only when the investor can explain why the disagreement exists, what evidence supports their view and what price makes acting on it worthwhile.
Being early, unpopular or misunderstood is not evidence of being right. The useful discipline is making a decision that can survive criticism and change when the facts do.
Key takeaways
- Define the assumption you dispute and the evidence that would distinguish your view from the strongest competing explanation.
- Set exposure limits and evidence gates before investing; an unpopular thesis does not justify an unlimited commitment.
- Reassess follow-ons at the current price. Being unable to sell an existing holding is different from deciding to put more money into it.
Write down the actual disagreement
“We believe in this market” is too broad. Identify the assumption other investors appear to reject.
For an illustrative industrial-software company, the disputed view might be: smaller manufacturers will adopt a new planning product without a lengthy consulting project. The conventional objection could be that implementation costs exceed the annual contract value.
Now the argument is testable. Relevant evidence includes implementation hours, customer willingness to supply data, support requirements and paid retention. The founder's ambition or the size of manufacturing as a sector cannot settle it.
Be careful about claiming to know the consensus. A few investors passing on a round may reflect mandate, price or timing rather than a shared view of the technology.
Explain why the opportunity remains available
If the evidence is strong, why have other investors not acted? There may be a credible reason: a mandate excludes the sector, the cheque is too small for a large fund or the evidence is difficult to interpret without specialist experience.
There may also be a less flattering explanation: the company has shown you selected customers, omitted service costs or offered terms that make the potential return unattractive.
List both explanations and investigate the strongest competing one. A supposed information advantage should survive an attempt to disprove it.
Set evidence gates before investing
For the software example, an investor might record three questions for the next six months:
- Can several unrelated customers deploy using a repeatable process?
- Does the recorded implementation cost include founder time and outside support?
- Do customers renew or expand after the initial enthusiasm fades?
Specify what would count as progress and what would weaken the case. Choose thresholds based on the company's economics, not because a round number looks tidy.
Some evidence takes longer to arrive than the company has cash. In that case, assess whether the proposed financing buys a meaningful test at all. A strong hypothesis with an unfunded proof point remains a difficult investment.
Size the position for uncertainty
A differentiated view does not justify an unlimited cheque. Set the maximum exposure before the emotional investment of helping the founder grows.
For illustration, an investor with £200,000 allocated to a multi-year programme might limit one initial position to £10,000, with a separate decision required before total exposure exceeds £20,000. Those figures are planning assumptions, not recommended limits.
The initial cheque purchases a particular exposure at particular terms. It does not reserve attractive terms in the next round unless the documents provide relevant rights, and even then exercising them requires capital.
Distinguish holding from investing more
An illiquid holding may be impossible to sell on reasonable terms. Continuing to own it is therefore not always an active vote of confidence.
A follow-on cheque is different: it commits new money. Write a new case using the current price, evidence and financing needs. Ask whether you would make that investment if you did not already own shares.
This question does not erase the benefits of information learned as an existing investor. It exposes whether those benefits are doing real analytical work or merely supporting a desire to avoid admitting an earlier mistake.
Decide what would make you change your mind
Separate setbacks in execution from failure of the central premise. One delayed deployment may be fixable. Repeated deployments requiring uneconomic custom work may challenge the product model itself.
Keep a dated record of changes to the thesis. If each disappointing result produces a new explanation that could not have been anticipated or tested, the view may have become impossible to falsify.
Non-consensus investing requires enough conviction to act before agreement arrives, and enough discipline to recognise when the disagreement was informative. A written hypothesis, bounded exposure and explicit evidence gates make both possible.
FAQ
What makes an investment non-consensus?
A material part of the investment case differs from a reasonably established market view. Identify the disputed assumption and evidence for both positions. A few investors passing on a deal may reflect price, mandate or timing rather than widespread disagreement with your thesis.
How is conviction different from stubbornness?
Conviction has an explanation and conditions under which the view would change. Stubbornness can survive any result by inventing a new justification. Record the decisive evidence gates before investing, then distinguish a fixable delay from a result that undermines the central premise.
Should a contrarian view justify a larger investment?
Its difference from consensus is not enough. Size the exposure around loss capacity, evidence quality, concentration and future funding needs. A small position can preserve the ability to learn and act later; a follow-on still needs a fresh decision at its own price.
Can a manager back an out-of-mandate deal through a separate SPV?
A separate vehicle may be possible, but it does not override existing obligations. Check allocation policies, conflicts, contractual restrictions, required consents and the sponsor's regulatory position. Explain the opportunity's separation clearly to investors instead of treating a new entity as automatic permission to proceed.
